The DOI matches its Crossref record; 103 of the 108 references it cites were found in a registry or an index.
ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
Open accessAbstract
Amyotrophic lateral sclerosis (ALS) is a devastating condition with an estimated mortality of 30,000 patients a year worldwide. The median reported survival time since onset ranges from 24 to 48 months. Riluzole is the only currently approved mildly efficacious treatment. Riluzole received marketing authorization in 1995 in the USA and in 1996 in Europe. In the years that followed, over 60 molecules have been investigated as a possible treatment for ALS. Despite significant research efforts, the overwhelming majority of human clinical trials (CTs) have failed to demonstrate clinical efficacy. In the past year, oral masitinib and intravenous edaravone have emerged as promising new therapeutics with claimed efficacy in CTs in ALS patients. Given their advanced phase of clinical development one may consider these drugs as the most likely near-term additions to the therapeutic arsenal available for patients with ALS. In terms of patient inclusion, CT with masitinib recruited a wider, more representative, less restrictive patient population in comparison to the only successful edaravone CT (edaravone eligibility criteria represents only 18% of masitinib study patients). The present manuscript reviews >50 CTs conducted in the last 20 years since riluzole was first approved. A special emphasis is put on the analysis of existing evidence in support of the clinical efficacy of edaravone and masitinib and the possible implications of an eventual marketing authorisation in the treatment of ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple small molecules with anti-inflammatory activity, including minocycline, masitinib, NP001, and celecoxib, have been tested for the treatment of ALS. Although most have failed, masitinib was found to be effective in the preceding clinical trials, and a Phase III clinical trial testing masitinib in ALS patients is ongoing.577”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [577]
Experimental — accuracy not yet measuredIn the citing paper
“Probiotics are considered to be dietary factors that can influence the human intestinal microbiota, which can affect the composition and structure of the intestinal flora; which, in turn, plays a role in protecting the intestinal epithelial barrier, inhibiting pathogen production, and regulating the immune system (3).”
From Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis (2023) · cites this paper as [3]
In the citing paper
“Through use of probiotics, the number of SCFA-producing microorganisms in the intestine can be increased (3).”
From Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis (2023) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,239
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V., Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,303
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447.pub3 · Cited by 1,123
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Jd, M., Lyon, M., & Moore, D. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447 · Cited by 910
Oxidative Stress in Neurodegenerative Diseases
Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J., & Filip, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9337-5 · Cited by 800
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
Preclinical research: Make mouse studies work
Perrin, S. (2014) · Nature · doi:10.1038/507423a · Cited by 668
Flagged first, then by citations
5 of the 108 references couldn’t be matched to a known paper.
Research works printed but not linked: 5
- ARISLA (Fondazione Italiana de Ricerca Per La Sclerosi Laterale), 2014, ALS Clinical Trials List.
- Bradley, 1995, A phase I/II study of recombinant brain-derived neurotrophic in patients with ALS., Ann. Neurol., 38
- Rosenfeld, 2001, “Creatine monohydrate in amyotrophic lateral sclerosis: preliminary results,” in Proceedings of the, American Academy of Neurology Annual Meeting
- Teva, 2010, News Release.
- Tohgi, 1999, Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis., Ann. Neurol., 46, 129, 10.1002/1531-8249(199907)46:1129::AID-ANA213.0.CO;2-Y · DOI
Cited by
Sorted by citations
Items 101–200 of 451
Goodwin, M. S., Sinyavskaya, O., Burg, F., O’Neal, V., Ceballos‐Diaz, C., Cruz, P. E., Lewis, J. M., Giasson, B. I., Davies, P., Golde, T. E., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.007 · Cited by 46
Therapeutic Potential of Polyphenols in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Novak, V., Rogelj, B., & Župunski, V. (2021) · Antioxidants · doi:10.3390/antiox10081328 · Cited by 42
Repurposing of Trimetazidine for amyotrophic lateral sclerosis: A study in SOD1G93Amice
Scaricamazza, S., Salvatori, I., Amadio, S., Nesci, V., Torcinaro, A., Giacovazzo, G., Primiano, A., Gloriani, M., Candelise, N., Pieroni, L., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15738 · Cited by 42
Rahmani, M., Negro, S., & Barcia, E. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106237 · Cited by 43
Trostchansky, A., Mastrogiovanni, M., Miquel, E., Rodríguez-Bottero, S., Palma, L. M., Cassina, P., & Rubbo, H. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00131 · Cited by 43
Christoforidou, E., Joilin, G., & Hafezparast, M. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01822-4 · Cited by 44
Cappella, M., Pradat, P., Querin, G., & Biferi, M. G. (2020) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200531 · Cited by 42
P2X7 Receptor Antagonism as a Potential Therapy in Amyotrophic Lateral Sclerosis
Ruiz‐Ruiz, C., Calzaferri, F., & Garcı́a, A. G. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00093 · Cited by 41
Tzeplaeff, L., Jürs, A. V., Wohnrade, C., & Demleitner, A. F. (2024) · Cells · doi:10.3390/cells13050452 · Cited by 39
Hong, D., Zhang, C., Wu, W., Lu, X., & Zhang, L. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1133546 · Cited by 38
Wages, P. A., Kim, H., Korade, Ž., & Porter, N. A. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m086991 · Cited by 38
Cieślak, M., Roszek, K., & Wujak, M. (2018) · Purinergic Signalling · doi:10.1007/s11302-018-9633-4 · Cited by 38
Maksymowicz, S., Barczewska, M., Grudniak, M., Siwek, T., Ołdak, T., Jezierska‐Woźniak, K., Gładysz, D., & Maksymowicz, W. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.243723 · Cited by 38
Dreger, M., Steinbach, R., Gaur, N., Metzner, K., Stubendorff, B., Witte, O. W., & Großkreutz, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.651651 · Cited by 37
Levin, L. A., Patrick, C., Choudry, N. B., Sharif, N. A., & Goldberg, J. L. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.964197 · Cited by 37
Egger, K., Aicher, H., Cumming, P. D., & Scheidegger, M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05353-6 · Cited by 37
Amyotrophic Lateral Sclerosis, FUS and Protein Synthesis Defects
Assoni, A. F., Foijer, F., & Zatz, M. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10489-8 · Cited by 37
Neuroprotective effect of CuATSM on neurotoxin-induced motor neuron loss in an ALS mouse model
Kuo, M., Beckman, J. S., & Shaw, C. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104495 · Cited by 35
SOD1 oligomers in amyotrophic lateral sclerosis
Choi, E. S., & Dokholyan, N. V. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.12.002 · Cited by 35
Classification of amyotrophic lateral sclerosis by brain volume, connectivity, and network dynamics
Thome, J., Steinbach, R., Großkreutz, J., Durstewitz, D., & Koppe, G. (2021) · Human Brain Mapping · doi:10.1002/hbm.25679 · Cited by 36
Martin, L. J., Adams, D. A., Niedzwiecki, M. V., & Wong, M. (2022) · Cells · doi:10.3390/cells11213448 · Cited by 35
Barros, A. N. A. B., Júnior, M. E. T. D., Pedrosa, L. F. C., & Leite-Lais, L. (2018) · Journal of Nutrition and Metabolism · doi:10.1155/2018/5678698 · Cited by 34
Rodríguez‐Cueto, C., García‐Toscano, L., Santos‐García, I., Gómez‐Almería, M., Gonzalo‐Consuegra, C., Espejo‐Porras, F., Fernández‐Ruíz, J., & de Lago, E. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15386 · Cited by 34
van Vliet, E. A., Iyer, A. M., Mesarosova, L., Çolakoğlu, H., Anink, J. J., van Tellingen, O., Maragakis, N. J., Shefner, J. M., Bunt, T., & Aronica, E. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz142 · Cited by 33
Intrathecal delivery of AAV-NDNF ameliorates disease progression of ALS mice
Cheng, W., Huang, J., Fu, X.-Q., Tian, W.-Y., Zeng, P.-M., Li, Y., & Luo, Z. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.09.018 · Cited by 32
Copper-ATSM as a Treatment for ALS: Support from Mutant SOD1 Models and Beyond
Nikseresht, S., Hilton, J. B. W., Kysenius, K., Liddell, J. R., & Crouch, P. J. (2020) · Life · doi:10.3390/life10110271 · Cited by 32
Quessada, C., Bouscary, A., René, F., Valle, C., Ferri, A., Ngo, S. T., & Loeffler, J. (2021) · Cells · doi:10.3390/cells10061449 · Cited by 33
Zakharova, M., & Abramova, A. A. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.314289 · Cited by 32
Synthetic and semi-synthetic antioxidants in medicine and food industry: a review
Tauchen, J., Huml, L., Jurášek, M., Regenstein, J. M., & Özoğul, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1599816 · Cited by 31
Sadr, A. S., Eslahchi, C., Ghassempour, A., & Kiaei, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-86211-4 · Cited by 31
Gomes, C., Sequeira, C., Likhite, S. B., Dennys, C. N., Kolb, S. J., Shaw, P. J., Vaz, A. R., Kaspar, B. K., Meyer, K., & Brites, D. M. T. O. (2022) · Cells · doi:10.3390/cells11071186 · Cited by 32
Ngo, S. T., Mi, J. D., Henderson, R. D., McCombe, P., & Steyn, F. J. (2017) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s120607 · Cited by 31
Maximizing the Survival of Amyotrophic Lateral Sclerosis Patients: Current Perspectives
Khairoalsindi, O. A., & Abuzinadah, A. R. (2018) · Neurology Research International · doi:10.1155/2018/6534150 · Cited by 35
The Role of Nucleocytoplasmic Transport Defects in Amyotrophic Lateral Sclerosis
Vanneste, J., & Bosch, L. V. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212175 · Cited by 32
Using Xenopus oocytes in neurological disease drug discovery
Zeng, S. L., Sudlow, L. C., & Berezin, M. Y. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1682993 · Cited by 30
Advanced therapeutic strategies targeting microglia: beyond neuroinflammation
Kwon, M. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01406-1 · Cited by 29
Steinbach, R., Gaur, N., Roediger, A., Mayer, T. E., Witte, O. W., Prell, T., & Großkreutz, J. (2020) · Human Brain Mapping · doi:10.1002/hbm.25258 · Cited by 28
Kong, J. S., Huang, X., Choi, Y., Yi, H., Kang, J.-S., Kim, S., Kim, J., Lee, H., Rim, Y. A., Ju, J. H., et al. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100581 · Cited by 28
Microglial crosstalk with astrocytes and immune cells in amyotrophic lateral sclerosis
Calafatti, M., Cocozza, G., Limatola, C., & Garofalo, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1223096 · Cited by 29
RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis
Mathis, S., & Masson, G. L. (2018) · Biomedicines · doi:10.3390/biomedicines6010009 · Cited by 28
Furr, J. W., Morales‐Scheihing, D., Manwani, B., Lee, J., & McCullough, L. D. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08568-0 · Cited by 29
Bond, L., Bowen, G., Mertens, B., Denson, K., Jordan, K., Vidakovic, B., & Mitchell, C. S. (2020) · Behavioral Sciences · doi:10.3390/bs10010033 · Cited by 27
Pathogenic Genome Signatures That Damage Motor Neurons in Amyotrophic Lateral Sclerosis
Yousefian-Jazi, A., Seol, Y., Kim, J., Ryu, H. L., Lee, J.-H., & Ryu, H. (2020) · Cells · doi:10.3390/cells9122687 · Cited by 29
Lastres‐Becker, I., Porras, G., Arribas-Blázquez, M., Maestro, I., Borrego‐Hernández, D., Boya, P., Cerdán, S., García‐Redondo, A., Martı́nez, A., & Martín‐Requero, Á. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063007 · Cited by 27
Embedded Palliative Care for Amyotrophic Lateral Sclerosis
Fahrner-Scott, K., Zapata, C. B., O’Riordan, D. L., Cohen, E., Rosow, L. K., Pantilat, S. Z., Lomen, C. E., & Bischoff, K. E. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000001124 · Cited by 27
Clinical and genetic features of amyotrophic lateral sclerosis patients withC9orf72mutations
Wiesenfarth, M., Günther, K., Müller, K., Witzel, S., Weiland, U., Mayer, K., Herrmann, C. H., Brenner, D., Schuster, J., Freischmidt, A., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad087 · Cited by 27
Yarborough, M. A., Bredenoord, A. L., D’Abramo, F., Joyce, N. C., Kimmelman, J., Ogbogu, U., Sena, E. S., Strech, D., & Dirnagl, U. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2006343 · Cited by 28
Volonté, C., Apolloni, S., & Sabatelli, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.006 · Cited by 26
Studying ALS: Current Approaches, Effect on Potential Treatment Strategy
Ustyantseva, E., Medvedev, S. P., & Zakian, S. M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41283-8_11 · Cited by 26
Potential of Cellular Therapy for ALS: Current Strategies and Future Prospects
Lin, T.-J., Cheng, K.-C., Wu, L.-Y., Lai, W.-Y., Ling, T., Kuo, Y., & Huang, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.851613 · Cited by 26
Badu-Mensah, A., Guo, X., Nimbalkar, S., Cai, Y., & Hickman, J. J. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121752 · Cited by 26
Nourelden, A. Z., Kamal, I., Hagrass, A. I., Tawfik, A. G., Elhady, M. M., Fathallah, A. H., Eshag, M. M. E., & Zaazouee, M. S. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06869-8 · Cited by 26
Variation across Species and Levels: Implications for Model Species Research
Striedter, G. F. (2019) · Brain Behavior and Evolution · doi:10.1159/000499664 · Cited by 28
Dell’Orco, M., Sardone, V., Gardiner, A. S., Pansarasa, O., Bordoni, M., Perrone‐Bizzozero, N. I., & Cereda, C. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105211 · Cited by 26
Zhang, W., Liu, D., Yuan, M., & Zhu, L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102307 · Cited by 28
Cuffaro, F., Lamminpää, I., Niccolai, E., & Amedei, A. (2024) · Nutrients · doi:10.3390/nu17010102 · Cited by 25
Saba, L., Viscomi, M. T., Martini, A., Caioli, S., Mercuri, N. B., Guatteo, E., & Zona, C. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104532 · Cited by 25
van Unnik, J. W. J., Meyjes, M., van Mantgem, M. R. J., van den Berg, L. H., & van Eijk, R. P. A. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105104 · Cited by 24
NADPH Oxidases in Neurodegenerative Disorders: Mechanisms and Therapeutic Opportunities
Fiadeiro, M. B., Diogo, J. C., Silva, A., Kim, Y., & Cristóvão, A. C. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0002 · Cited by 25
Lake, J., Storm, C. S., Makarious, M. B., & Bandrés‐Ciga, S. (2021) · Cells · doi:10.3390/cells10051030 · Cited by 24
Martín-Cámara, O., Arribas, M., Wells, G., Morales-Tenorio, M., Martín‐Requero, Á., Porras, G., Martı́nez, A., Giorgi, G., López‐Alvarado, P., Lastres‐Becker, I., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01255 · Cited by 27
Delila, L., Nebie, O., Le, N. T. N., Barro, L., Chou, M., Wu, Y., Watanabe, N., Takahara, M., Buée, L., Blum, D. L., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10360 · Cited by 24
KIT as a therapeutic target for non-oncological diseases
Martínez‐Antón, A., Gras, D., BOURDIN, A. A., Dubreuil, P. C., & Chanez, P. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.008 · Cited by 24
Analysis of shared underlying mechanism in neurodegenerative disease
Butler, R., Bradford, D. R., & Rodgers, K. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1006089 · Cited by 24
Bereman, M. S., Kirkwood‐Donelson, K. I., Sabaretnam, T., Furlong, S., Rowe, D. B., Guillemin, G. J., Mellinger, A. L., & Muddiman, D. C. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00216 · Cited by 23
Swindell, W. R., Bojanowski, K., Kindy, M. S., Chau, R. M. W., & Ko, D. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0135-7 · Cited by 23
Chagarovskiy, A. O., Kuznetsov, V. V., Ivanova, O. A., Goloveshkin, A. S., Levina, I. I., Makhova, N. N., & Trushkov, I. V. (2019) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201900579 · Cited by 23
Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics?
Roberts, B., Theunissen, F., Mastaglia, F. L., Akkari, P. A., & Flynn, L. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169364 · Cited by 25
Nango, H., Tsuruta, K., Miyagishi, H., Aono, Y., Saigusa, T., & Kosuge, Y. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00366-w · Cited by 24
Incorporating upper motor neuron health in ALS drug discovery
Dervishi, I., & Özdi̇nler, P. H. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.027 · Cited by 24
Open Science Meets Stem Cells: A New Drug Discovery Approach for Neurodegenerative Disorders
Han, C., Chaineau, M., Chen, C. X. ‐., Beitel, L. K., & Durcan, T. M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00047 · Cited by 22
Vascular regression precedes motor neuron loss in the FUS (1-359) ALS mouse model
Crivello, M., Hogg, M. C., Jirström, E., Halang, L., Woods, I., Rayner, M., Coughlan, K. S., Lewandowski, S. A., & Prehn, J. H. M. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.040238 · Cited by 25
Alam, M., Yadav, R. K., Minj, E., Tiwari, A., & Mehan, S. (2020) · Current Molecular Pharmacology · doi:10.2174/1566524020666200427214356 · Cited by 21
Smith, A. S. T., Chun, C., Hesson, J., Mathieu, J., Valdmanis, P. N., Mack, D. L., Choi, B., Kim, D., & Bothwell, M. A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.728707 · Cited by 22
Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis
Estévez-Silva, H. M., Mediavilla, T., Giacobbo, B. L., Liu, X., Sultan, F. R., & Marcellino, D. J. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15608 · Cited by 21
Neuron-Specific HuR-Deficient Mice Spontaneously Develop Motor Neuron Disease
Sun, K. Y., Li, X., Chen, X., Bai, Y., Zhou, G., Kokiko‐Cochran, O. N., Lamb, B. T., Hamilton, T. A., Lin, C., Lee, Y., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701501 · Cited by 22
Bashford, J. A., Wickham, A. P., Iniesta, R., Drakakis, E. M., Boutelle, M. G., Mills, K. R., & Shaw, C. (2019) · Clinical Neurophysiology · doi:10.1016/j.clinph.2019.09.015 · Cited by 20
Pathogenic or protective? Neuropeptide Y in amyotrophic lateral sclerosis
Clark, C. M., Clark, R. M., Hoyle, J. A., & Dickson, T. C. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15125 · Cited by 20
Ursu, A., Wang, K. W., Bush, J. A., Choudhary, S., Chen, J. L., Baisden, J. T., Zhang, Y., Gendron, T. F., Petrucelli, L., Yildirim, I., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00049 · Cited by 20
ROS scavengers decrease γH2ax spots in motor neuronal nuclei of ALS model mice in vitro
Junghans, M., John, F., Cihankaya, H., Schliebs, D., Winklhofer, K. F., Bader, V., Matschke, J., Theiß, C., & Matschke, V. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.963169 · Cited by 20
Rifai, O. M., Longden, J., O’Shaughnessy, J., Sewell, M. D. E., Pate, J. A., McDade, K., Daniels, M. J. D., Abrahams, S., Chandran, S., McColl, B. W., et al. (2022) · The Journal of Pathology · doi:10.1002/path.6008 · Cited by 20
Why should we care about astrocytes in a motor neuron disease?
Dittlau, K. S., & Bosch, L. V. D. (2023) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1047540 · Cited by 24
The Breakdown of Neurovascular Barriers: Molecular Mechanisms of Tight Junction Dysfunction
Gopal, S. S., Kaur, M., Lanzkron, S., & Srivastava, A. K. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05592-z · Cited by 20
Robinson, K. J., Yuan, K. C., Don, E. K., Hogan, A. L., Winnick, C. G., Tym, M. C., Lucas, C. W., Shahheydari, H., Watchon, M., Blair, I. P., et al. (2018) · Zebrafish · doi:10.1089/zeb.2018.1588 · Cited by 19
Matrin3: Disorder and ALS Pathogenesis
Salem, A., Wilson, C. J., Rutledge, B. S., Dilliott, A. A., Farhan, S. M. K., Choy, W., & Duennwald, M. L. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.794646 · Cited by 20
Chemotherapeutic agent 5-fluorouracil increases survival of SOD1 mouse model of ALS
Rando, A., de la Torre, M., Martínez‐Muriana, A., Zaragoza, P., Musarò, A., Hernández, S., Navarro, X., Toivonen, J. M., & Osta, R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210752 · Cited by 19
Aragón-González, A., Shaw, A. C., Kok, J. R., Roussel, F. S., Souza, C. D. S., Granger, S. M., Vetter, T. A., de Diego‐Otero, Y., Meyer, K., Beal, S. N., et al. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00528-6 · Cited by 18
Bonet, L. F. S., Loureiro, J. P., Pereira, G. R. C., Silva, A. N. R. D., & Mesquita, J. F. D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258061 · Cited by 18
Jiménez-Villegas, J., Kirby, J., Mata, A., Cadenas, S., Turner, M. R., Malaspina, A., Shaw, P. J., Cuadrado, A., & Rojo, A. I. (2022) · Antioxidants · doi:10.3390/antiox11101897 · Cited by 21
Al‐kharboosh, R., Perera, J., Bechtle, A. R., Bu, G., & Quiñones‐Hinojosa, A. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1093 · Cited by 20
Effects of Physical Activity on Amyotrophic Lateral Sclerosis
Maugeri, G., & D’Agata, V. (2020) · Journal of Functional Morphology and Kinesiology · doi:10.3390/jfmk5020029 · Cited by 19
Russo, A., Putaggio, S., Tellone, E., Calderaro, A., Cirmi, S., Laganà, G., Ficarra, S., Barreca, D., & Patanè, G. T. (2025) · Molecules · doi:10.3390/molecules30061211 · Cited by 18
Cortical Hyperexcitability in the Driver’s Seat in ALS
Gunes, Z. I., Kan, V. W. Y., Jiang, S., Logunov, E., Ye, X., & Liebscher, S. (2022) · Clinical and Translational Neuroscience · doi:10.3390/ctn6010005 · Cited by 18
SERCA pump as a novel therapeutic target for treating neurodegenerative disorders
Dahl, R. S., & Борисович, Б. И. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150748 · Cited by 18
Pozzi, S., Thammisetty, S. S., & Julien, J. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0634-3 · Cited by 17
High-throughput drug screens for amyotrophic lateral sclerosis drug discovery
McGown, A., & Stopford, M. J. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1533953 · Cited by 17
Glia in amyotrophic lateral sclerosis and spinal cord injury: common therapeutic targets
Ban, J., Sámano, C., Mladinić, M., & Munitić, I. (2019) · Croatian Medical Journal · doi:10.3325/cmj.2019.60.109 · Cited by 20
Watts, M. E., Wu, C., & Rubin, L. L. (2019) · Journal of Experimental Neuroscience · doi:10.1177/1179069519862798 · Cited by 17
Beckers, J., & Damme, P. V. (2025) · Autophagy Reports · doi:10.1080/27694127.2025.2474796 · Cited by 19
Anwar, A., Yameen, D., Masood, M., Parvez, S., & Haque, M. M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148589 · Cited by 16
Metadata
- Authors
- Petrov, D., Mansfield, C., Moussy, A., & Hermine, O.
- Affiliations
- AB Science (France) (FR)
- Hôpital Necker-Enfants Malades (FR)
- Corresponding author
- Hermine, Olivier
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-03-22
- Volume
- 9
- Pages
- 68-68
- ISSN
- 1663-4365 (ISSN-L)
- PMC
- PMC5360725
- OpenAlex
- W2597399186
- Cited by
- 451
- References
- 108
- Citations by year
- 2026: 28 · 2025: 41 · 2024: 45 · 2023: 46 · 2022: 65 · 2021: 63 · 2020: 53 · 2019: 52 · 2018: 50 · 2017: 8
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Aging Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-11-LABX-0051)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- amyotrophic lateral sclerosis, clinical trial failure, riluzole, edaravone, masitinib, drug development, clinical efficacy, patient selection criteria, drug approval, neurodegenerative disease therapeutics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
